PASSReviewer 1· 90% conf
This is a human RCT, so bench-specific criteria (replicates, wet-lab controls, independent replication) are not applicable. Randomization, blinding, power analysis, inclusion/exclusion, and missing-data/outlier handling are all adequately described.
Evidence
direct quote[Methods, Randomization]
“Participants were randomly assigned (1:1:1:1:1:1:1:1:1 ratio) to one of the following nine treatment groups using a centralized web-based interactive response system”paraphrase[Methods, Statistical analysis]
“The planned sample size of 495 participants was estimated to provide over 80% statistical power to detect a difference between any active treatment group and placebo with respect to the primary endpoint using a two-sided t-test with significance level of 0.05.”direct quote[Methods, Procedures]
“The participant, investigator and sponsor were blinded to bimagrumab dose or placebo−bimagrumab until database lock to avoid bias in reporting adverse events and efficacy.”PASSReviewer 2· 95% conf
The study design is rigorous for a phase 2 trial: randomized, double-blind (for bimagrumab), with a pre-specified power analysis, clear inclusion/exclusion criteria, and a centralized randomization system.
Evidence
paraphrase[Methods, Randomization]
“Participants were randomly assigned (1:1:1:1:1:1:1:1:1 ratio) to one of the following nine treatment groups using a centralized web-based interactive response system.”direct quote[Methods, Procedures]
“The trial used commercially available semaglutide in prefilled pen injectors, which precluded the possibility of blinding.”paraphrase[Methods, Statistical analysis]
“The planned sample size of 495 participants was estimated to provide over 80% statistical power to detect a difference between any active treatment group and placebo with respect to the primary endpoint using a two-sided t-test with significance level of 0.05.”